Allarity Therapeutics announced significant progress in its Phase 2 stenoparib trial for advanced ovarian cancer, with two patients showing remarkable treatment benefits exceeding 14 months. The company maintains a strong cash position of $18.5 million as of September 30, 2024, sufficient to initiate the next FDA registrational trial.The trial involves a revised protocol implemented in Q1 2023, featuring a twice-daily dosing regimen of stenoparib (200mg morning, 400mg evening) for patients selected using Allarity's DRP companion diagnostic. The enrolled patients, most previously treated with PARP inhibitors, represent a heavily pretreated population with limited therapeutic options.The company has expanded its Allarity Medical Laboratory services to external biotech clients, establishing revenue-generating operations through Drug Response Predictor analysis and gene expression services. This strategic expansion reduces laboratory costs while advancing the position of Allarity's proprietary DRP platform within the industry.

Allarity Therapeutics announced significant progress in its Phase 2 stenoparib trial for advanced ovarian cancer, with two patients showing remarkable treatment benefits exceeding 14 months. The company maintains a strong cash position of $18.5 million as of September 30, 2024, sufficient to initiate the next FDA registrational trial.The trial involves a revised protocol implemented in Q1 2023, featuring a twice-daily dosing regimen of stenoparib (200mg morning, 400mg evening) for patients selected using Allarity's DRP companion diagnostic. The enrolled patients, most previously treated with PARP inhibitors, represent a heavily pretreated population with limited therapeutic options.The company has expanded its Allarity Medical Laboratory services to external biotech clients, establishing revenue-generating operations through Drug Response Predictor analysis and gene expression services. This strategic expansion reduces laboratory costs while advancing the position of Allarity's proprietary DRP platform within the industry.